The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump.

Provided here are methods of treating Niemann-Pick disease type C (NPC) in a subject or delaying the onset of NPC in a subject by administering to the subject an immunomodulator, or a modulator of amyloid precursor protein (APP) function, or a combination thereof.

Provided here are methods of treating Niemann-Pick disease type C (NPC) in a subject or delaying the onset of NPC in a subject by administering to the subject an immunomodulator, or a modulator of amyloid precursor protein (APP) function, or a combination thereof.

The present disclosure provides compositions and methods for treatment and prevention of cardiorenal damage. In particular, provided herein are compositions comprising proANP.sub.31-67 for use in treating and preventing cardiorenal damage in subjects with heart failure.

This invention relates to a method for repairing and reconstructing a damaged or non-functional muscle, in particular to a method and a tool kit using in vitro primed motor endplate-expressing muscle progenitor cells (MPCs) to promote innervation of the damaged or non-functional muscle using an agent without any genetic manipulation. This method is particularly useful for repairing or reconstructing damaged or non-functional head and neck muscles, and urinary detrusor bladder muscle.

A method for preventing, treating or delaying myocardial damage in a mammal using neuregulin and a composition. An administration method for, an administration frequency of and an administration dosage of a pharmaceutical formulation or composition for reducing myocardial damage. It can be proved in a rat myocardial damage model that neuregulin can improve the cardiac function after myocardial infarction, suggesting that neuregulin can be used for preventing, treating, or delaying myocardial infarction damage.

Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

A drug delivery system and methods of using such for delivering a peglyated therapeutic agent to heart. The drug delivery system may comprise an antibody embedded in a hydrogel, comprising one or more biodegradable polymers, up to about 60% of which contain inter-chain or intra-chain covalent crosslinks.

Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.